#USA #Deerfield #ESTEVE #TerSera #Quzyttir

ESTEVE's Strategic Move in the US Pharmaceutical Market

In a significant development in the healthcare sector, ESTEVE, a global pharmaceutical company, announced the acquisition of the injectable specialty drug division from TerSera Therapeutics. This strategic acquisition positions ESTEVE to enhance its operational footprint in the United States, allowing access to two highly specialized assets in the pharmaceutical market as well as a dedicated team in sales, marketing, and medical expertise.

The acquisition includes two key products: Prialt® and Quzyttir®. Prialt® is notably the only non-opioid agent approved by the FDA for severe chronic pain treatment through intrathecal infusion, specifically for adults who cannot tolerate or have not responded to standard treatments. Currently, ESTEVE markets Prialt® in Europe, and this move aims to introduce the drug to the vast U.S. market. On the other hand, Quzyttir® is the first and only second-generation injectable antihistamine approved to treat acute urticaria in both adults and children aged six months and above.

With this deal, ESTEVE will secure global rights for Quzyttir® in all territories except China and will further solidify its rights for Prialt® worldwide. Staffan Schüberg, CEO of ESTEVE, expressed enthusiasm at welcoming TerSera's talented team, aligning with the company's commitment to address significant unmet medical needs through specialized solutions.

```
"Our vision is to provide highly specialized solutions where there is an important unmet medical need. Adding Quzyttir® to our portfolio and expanding our presence in the US market with Prialt® not only strengthens our capabilities in these specialized treatments but also accelerates our development in the US, the largest pharmaceutical market in the world."
```

Edward Donovan, CEO of TerSera, echoed these sentiments, asserting that ESTEVE's longstanding partnership for Prialt® in Europe made it the ideal future owner of the injectable specialty division. Donovan emphasized that the transition would facilitate the continuation of strong momentum around Prialt® and Quzyttir®, allowing TerSera to refine its focus on core therapeutic areas like oncology and rare diseases.

This acquisition underscores ESTEVE's growth trajectory in the United States, which began in 2024 with another acquisition targeting rare and ultra-rare diseases in endocrinology and related fields. Subsequent expansion efforts included acquiring licenses for biologics aimed at pediatrics, further extending their specialized portfolio.

The transaction is anticipated to close in the first quarter of 2026, contingent on regulatory approvals. Financial counsel for ESTEVE during this transaction was provided by Perella Weinberg Partners, while Arnold & Porter offered legal advice. Meanwhile, TerSera was represented by Leerink Partners as the main financial advisor and Kirkland & Ellis as legal counsel.

A Brief Overview of ESTEVE and TerSera Therapeutics

Founded in 1929 and headquartered in Barcelona, ESTEVE operates with a clear mission to improve people's lives worldwide. With a significant international presence, ESTEVE focuses on providing highly specialized treatments to meet the substantial medical needs across various therapeutic areas. In addition to its pharmaceutical innovations, ESTEVE also offers comprehensive contract manufacturing services and specializes in the production of active pharmaceutical ingredients.

Conversely, TerSera Therapeutics, formed in 2016, specializes in oncology and rare diseases, carving out a reputation for delivering unique therapeutic products that yield meaningful patient outcomes while also being recognized as a top workplace in 2025.

As both companies move forward with this acquisition, the healthcare landscape is poised to become more competitive with enhanced offerings in the specialized drug sector, ultimately benefitting patients across the globe.